Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cancer Vaccines01:30

Cancer Vaccines

972
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
972
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guarding epithelial integrity: origins of adaptive immunity and cancer immunosurveillance over time and space.

Journal for immunotherapy of cancer·2026
Same author

DEA hypothesis: disinhibition, enhancing recognition, and alerting the host are the three pillars of effective cancer immunotherapy.

Journal for immunotherapy of cancer·2026
Same author

DNA hypomethylating agents preserve T cell stemness and potentiate the efficacy of CD3-bispecific antibodies.

Cancer immunology research·2026
Same author

Immunological consequences of chemotherapy: implications for cancer immunotherapy.

Journal for immunotherapy of cancer·2026
Same author

Pancreatic Lymphatics in Health and Disease: Evolution, Embryology, and Neural Control.

Lymphatics·2026
Same author

Ernest C Borden (1939-2026): in memoriam for a life of caring, researching, leading, teaching and serving.

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Jan 17, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K

Second signals for cancer immunotherapy.

Scott H Olejniczak1, Michael T Lotze2, Dimitris Skokos3

  • 1Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA lotzemt@upmc.edu scott.olejniczak@roswellpark.org dimitris.skokos@regeneron.com.

Journal for Immunotherapy of Cancer
|September 24, 2025
PubMed
Summary

The CD28 co-stimulatory receptor is crucial for effective cancer immunotherapy. Understanding T cell co-stimulation mechanisms, including CTLA-4 and PD-1 pathways, is vital for developing new cancer treatments.

Keywords:
Immune Checkpoint InhibitorImmunotherapyMajor histocompatibility complex - MHCT cellco-stimulatory molecules

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

3.0K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K

Related Experiment Videos

Last Updated: Jan 17, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

3.0K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • The CD28 receptor plays a critical role in T cell co-stimulation for cancer immunotherapy.
  • Tumors evade immune detection by inhibiting T cell co-stimulation via pathways like CTLA-4 and PD-1.
  • Understanding T cell co-stimulatory receptor complexities is essential for advancing cancer treatments.

Purpose of the Study:

  • To highlight recent studies on T cell co-stimulatory receptors in cancer.
  • To discuss the contributions of these studies to understanding cancer immunotherapy.

Main Methods:

  • Review of recent scientific literature.
  • Commentary on emerging research findings.
  • Analysis of T cell co-stimulation mechanisms.

Main Results:

  • Recent studies reveal intricate mechanisms of T cell co-stimulation in cancer.
  • Inhibitory pathways (CTLA-4, PD-1) are key targets for immune evasion.
  • Alternative co-stimulation strategies show promise in cancer therapy.

Conclusions:

  • Renewed focus on CD28 and other co-stimulatory receptors is driving cancer immunotherapy innovation.
  • Targeting T cell co-stimulation pathways offers therapeutic opportunities.
  • Further research into T cell co-stimulatory receptors will enhance cancer treatment efficacy.